Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Akeso's Ivonescimab Plus Chemotherapy Cuts Death Risk 25% Versus Durvalumab Regimen in Biliary Tract Cancer Trial

By Public Technologies
  • Akeso announced Oct. 26, 2026, that ivonescimab with chemotherapy improved overall survival versus durvalumab with chemotherapy in first-line advanced biliary tract cancer.
  • Median overall survival reached 14.9 months versus 12.1 months; the risk of death fell 25% (P=0.0031).
  • Median progression-free survival was 8.4 months versus 5.8 months; response rates reached 53.8% versus 32.5%.
  • The Phase III HARMONi-GI1 trial enrolled 682 participants; no new safety signals emerged.
  • The ivonescimab combination has been proposed for priority review by China's National Medical Products Administration for first-line biliary tract cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12382417), on October 25, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.